HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

HMCAZ5

mouse-human chimeric antibody against DR5 receptor protein with antineoplastic properties

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        HMCAZ5: 1
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        HMCAZ5: 1
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        HMCAZ5: 1

Experts

1.	Liu, Shilian: 1 article (09/2012)
2.	Liu, Yanxin: 1 article (09/2012)
3.	Qiu, Yuhe: 1 article (09/2012)
4.	Shi, Juan: 1 article (09/2012)
5.	Zhang, Zhixin: 1 article (09/2012)
6.	Zheng, Dexian: 1 article (09/2012)

Related Diseases

1.

Neoplasms (Cancer)

09/01/2012 - "Moreover, HMCAZ5 alone suppresses tumor growth, and EPB augments the tumoricidal activity in human colorectal and hepatocellular tumor xenografts in athymic nude mice. "
09/01/2012 - "These data suggest that the anti-DR5 chimeric antibody HMCAZ5 may have a clinical use and represents a useful immunological strategy, in combination with chemotherapy, for the treatment of cancer."
09/01/2012 - "Highly purified HMCAZ5 exhibits a high affinity for the receptor that is equal to the parental mouse antibody, induces apoptosis in various cancer cells but not in normal hepatocytes, and elicits both antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in various human cancer cells. "
09/01/2012 - "The anthracycline anticancer drug epirubicin (EPB) synergizes the cytotoxicity of HMCAZ5 in cancer cells by upregulating DR5 expression on the cell surfaces, enhancing p53 expression, Bid cleavage, and JNK phosphorylation and downregulating c-FLIP expression and Akt phosphorylation. "

Related Drugs and Biologics

1.	Anthracyclines
2.	Epirubicin (Ellence)
3.	Complement System Proteins (Complement)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)